ClinicalTrials.gg

Program

golcadomide

Also written as “BMS-986369”, “Golcadomide” and “CC-99282”.

Its studies are mostly in Lymphoma, Follicular · Lymphoma, Non-Hodgkin · Lymphoma, T-Cell · Kidney Failure, Chronic · Lymphoma, B-Cell, led by Bristol-Myers Squibb.

Furthest: phase 3, since Mar 27, 202411 company-led studies, 7 open or runningNext primary completion: Dec 14, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb117 open or runningphase 3since Mar 27, 2024Apr 16, 2019Dec 14, 2026phase 1 · NCT07763418
  • Named in Bristol-Myers Squibb’s own pipeline as golcadomide, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 16, 2019First study: phase 2 study in Lymphoma, Non-HodgkinFirst studyNCT03930953 · 438 enrolled · United States, Argentina, Austria and more
  2. Jun 1, 2020Phase 1 study in Lymphoma, Non-HodgkinNCT04434196 · 16 enrolled · United States, Austria, Canada and more
  3. May 7, 2021Phase 1 study in Lymphoma, B-CellNCT04884035 · 224 enrolled · United States, Australia, Greece and more
  4. Apr 25, 2022Phase 1 study in Healthy VolunteerNCT05350800 · 68 enrolled · United States
  5. Oct 3, 2022Phase 1 study in Healthy ParticipantsNCT05567510 · 8 enrolled · United States
  6. Aug 28, 2023Phase 2 study in RecurrenceNCT06035497 · 83 enrolled · Japan
  7. Mar 27, 2024Phase 3 study in LymphomaNCT06356129 · 850 enrolled · United States, Argentina, Australia and more
  8. May 17, 2024Phase 2 study in Lymphoma, FollicularNCT06425302 · 95 enrolled · United States, Australia, Brazil and more
  9. Jul 30, 2024Phase 1 study in Liver DiseasesNCT06535399 · 29 enrolled · United States
  10. Mar 28, 2025Phase 3 study in Lymphoma, FollicularNCT06911502 · 400 planned · United States, Australia, Brazil and more
  11. Aug 10, 2026Phase 1 study in Kidney Failure, ChronicNCT07763418 · 30 planned · United States

Ahead

  1. Dec 14, 2026Primary completion: phase 1 study in Kidney Failure, ChronicNCT07763418
  2. Apr 7, 2027Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT03930953
  3. Aug 9, 2027Primary completion: phase 3 study in LymphomaNCT06356129
  4. Apr 24, 2028Primary completion: phase 3 study in Lymphoma, FollicularNCT06911502

TargetBeta

“A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, golcadomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and target…”NCIt, read by Claude

Other programs on CRBN

ProgramCompanyFurthest phaseStudies
LenalidomideruleBristol-Myers Squibbphase 4109
pomalidomideruleBristol-Myers Squibbphase 451
mezigdomideBristol-Myers Squibbphase 312
Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506Bristol-Myers Squibbphase 11
HRS-3738Jiangsu HengRui Medicinephase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07763418Kidney Failure, Chronic · United States1RecruitingDec 14, 202630
NCT06911502Lymphoma, Follicular · United States, Australia, Brazil and more3RecruitingApr 24, 2028400
NCT06535399Liver Diseases · United States1CompletedNov 12, 202529
NCT06425302Lymphoma, Follicular · United States, Australia, Brazil and more2Active, not recruitingJun 19, 202695
NCT06356129Lymphoma · United States, Argentina, Australia and more3Active, not recruitingAug 9, 2027850
NCT06035497Recurrence · Japan2Active, not recruitingAug 11, 202683
NCT05567510Healthy Participants · United States1CompletedDec 27, 20228
NCT05350800Healthy Volunteer · United States1CompletedMay 4, 202368
NCT04884035Lymphoma, B-Cell · United States, Australia, Greece and more1Active, not recruitingDec 1, 2028224
NCT04434196Lymphoma, Non-Hodgkin · United States, Austria, Canada and more1CompletedMay 21, 202416
NCT03930953Lymphoma, Non-Hodgkin · United States, Argentina, Austria and more2Active, not recruitingApr 7, 2027438

How it is read

Names in the registry

  • “BMS-986369”, 4 entries
  • “Golcadomide”, 4 entries
  • “CC-99282”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.